A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomolgus monkey (Macaca fascicularis) and man

Xenobiotica

Volumn 29, Issue 5, 1999, Pages 467-482

  Weaver, R J ^a   Dickins, M ^b   Burke, M D ^c  

^a Servier Research and Development   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA NAPHTHOFLAVONE; CYTOCHROME P450 REDUCTASE; DEXTROMETHORPHAN; OXYGENASE; PENTOXYRESORUFIN; PHENOBARBITAL; RESORUFIN DERIVATIVE; RIFAMPICIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MACACA; MALE; NONHUMAN; PROTEIN EXPRESSION;

ADULT; ANIMALS; BETA-NAPHTHOFLAVONE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOBLOTTING; MACACA FASCICULARIS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PHENOBARBITAL; RIFAMPIN; STEROID HYDROXYLASES;

ANIMALIA; MACACA; MACACA FASCICULARIS;

EID: 0033058613     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238489     Document Type: Article

References (58)

1. ABEL, S. M., MAGGS, J. L., BACK, D. J. and PARK, B. K., 1992, Cortisol metabolism by human liver in invitro-1 metabolite identification and inter-individual variability. Journal of Steroid Biochemistry and Molecular Biology, 43, 713-719.
2. BERTHOU, F., GUILLOIS, B., RICHE, C., DREANO, Y., JACQZ-AIGRAIN, E. AND BEAUNE, P. H., 1992, Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica, 22, 671-680.
3. BURKE, M. D. and MAYER, R. T. 1983, Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P450-binding of phenoxyazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chemico-Biological Interactions, 45, 243-258.
4. BURKE, M. D., THOMPSON, S., ELCOMBE, C. R., HALPERT, J., HAAPARANTA, T. and MAYER, R. T., 1985, Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochemical Pharmacology, 34, 3337-3345.
5. BURKE, M. D., THOMPSON, S., WEAVER, R. J., WOLF, C. R. and MAYER, R. T., 1994, Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochemical Pharmacology, 48, 923-936.
6. CHALLINER, M. R., PARK, B. K., ODUM, J., ORTON, T. C. and PARKER, G. L., 1980, The effects of phenobarbitone on urinary 6β-hydroxycortisol excretion and hepatic enzyme activity in the marmoset monkey (Callithrix jacchus). Biochemical Pharmacology, 19, 3319-3324.
7. DAVIS, C. D., ADAMSON, R. H. and SNYDERWINE, E. G., 1993, Studies on the mutagenic activation of heterocyclic amines by cynomolgus monkey, rat and human liver microsomes show that cynomolgus monkeys have a low capacity to N-oxidize the quinoxaline-type heterocyclic amines. Cancer Letters, 73, 95-104.
8. DISTELRATH, L. M., REILLY, P. E. B., MARTIN, M. V., DAVIS, G. G., WILKINSON, G. R. and GUENGERICH, F. P., 1985, Purification and characterization of the human liver microsomal cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 260, 9057-9067.
9. EDWARDS, R. J., MURRAY, B. P., MURRAY, S., SCHULZ, T., NEUBERT, D., GANT, T. W., THORGEIRSSON, S. S., BOOBIS, A. R. and DAVIES, D. S., 1994, Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis, 15, 829-836.
10. EGGER, H., ITTERLY, W., JOHN, V., RODEBAUGH, R., SHIMANSKAS, C., STANCATO, F. and KAPOOR, A., 1988, Disposition and metabolism of prinomide in laboratory animals. Drug Metabolism and Disposition, 16, 568-575.
11. FORRESTER, L. M., HENDERSON, C. J., GLANCY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLEAN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359-368.
12. FUHR, U., DOEHMER, J., BATTULA, N., WOLFEL, C., FLICK, I., KUDLA, C., KEITA, Y. and STAIB, A., 1993, Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Toxicology, 82, 169-189.
13. GED, C., ROUILLON, J. M., PICHARD, L., COMBALBERT, J., BRESSOT, N., BORIES, P., MICHEL, H, BEAUNE, P. AND MAUREL, P., 1989, The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. British Journal of Clinical Pharmacology, 28, 373-387.
14. GOLDSTEIN, J. A., FALETTO, M. B., ROMKESSPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
15. JACQZ-AIGRAIN, E., FUNCK-BRENTANO, C. and CRESTEIL, T., 1993, CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197-204.
16. JACQZ-AIGRAIN, E., GUEGUEN, M., ZANGER, U. M., ROBIEUX, I. and ALVAREZ, F., 1991, Cytochrome P450IID subfamily in non-human primates: catalytical and immunological characterization. Biochemical Pharmacology, 41, 1657-1663.
17. JONES, C. R., GUENGERICH, F. P., RICE, J. M. and LUBET, R. A., 1992, Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. Pharmacogenetics, 2, 160-172.
18. KASTNER, M. and NEUBERT, D., 1994, Characterization of cytochromes P-450 purified from untreated and 14C-2,3,7,8-tetrachlorodibenzo-p-dioxin-treated marmoset monkeys: identification of the major form as a possible orthologue of P-450 1A2. Biochimica et Biophysica Acta, 1200, 7-10.
19. KASTNER, M., SCHULZ-SCHALGE, T. and NEUBERT D., 1989, Purification and properties of cytochrome P-450 from liver microsomes of phenobarbital-treated marmoset monkeys Toxicology Letters, 45, 261-270.
20. KOJO, A., PELLINEN, P., JUVONEN, R., RAUNIO, H., PELKONEN, O. and PASANEN, M., 1996, Distinct responses of mouse hepatic CYP enzymes to corn oil and peroxisomes proliferators. Biochemical Pharmacology 51, 1137-1143.
21. KOMORI, M., KIKUCHI, O., KITADA, M. and KAMATAKI, T., 1992a, Molecular cloning of monkey P450 1A1 cDNA and expression in yeast. Biochimica et Biophysica Acta, 1131, 23-29.
22. KOMORI, M., KIKUCHI, O., SAKUMA, T., FUNAKI, J., KITADA, M. and KAMATAKI, T., 1992b, Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. Biochimica et Biophysica Acta, 1171, 141-146.
23. KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry, 162, 24-32.
24. KUHNZ, W., HOYER, G. A., BACKUS, S. and JAKOBS, U., 1994, Metabolism of the steroidal aromatase inhibitor atamestane in rats, cynomolgus monkeys and humans: isolation and identification of the major metabolites. European Journal of Drug Metabolism and Pharmacokinetics, 19, 137-150.
25. LEE, Q. P., FANTEL, A. G. and JUCHAU, M. R., 1991, Human embryonic cytochrome P450s: phenoxazone ethers as probes for expression of functional isoforms during organogenesis. Biochemical Pharmacology, 42, 2377-2385.
26. LI, Y., LI, N. Y. and SELLERS, E. M., 1997, Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. European Journal of Drug Metabolism and Pharmacokinetics, 22, 295-304.
27. LONGO, V., MAZZACCARO, A., VENTURA, P. and GERVASI, P. G., 1992, Drug-metabolizing enzymes in respiratory nasal mucosa and liver of Cynomolgus monkey. Xenobiotica, 22, 427-431.
28. LOWRY, O. H., ROSEBROUGH, N. J. FARR, A. L. and RANDALL, A. J., 1951, Protein measurement with the Folin phenol reagents. Journal of Biological Chemistry, 193, 265-275.
29. LUBET, R. A., SYI, J.-L., NELSON, J. O. and NIMS, R. W., 1990, Induction of hepatic cytochrome P450 mediated alkoxyresorufin O-dealkylase activities in different species by prototype P450 inducers. Chemico-Biological Interactions, 75, 325-339.
30. MA, Y., PEAKMAN, M., LOBO-YEO, A., WEN, L., LENZI, M., GAKEN, J., FARZANEH, F., MIELI-VERGANI, G., BIANCHI, F. B. and VERGANI, D., 1994, Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clinical and Experimental Immunology, 97, 94-99.
31. MENNES, W. C., VAN HOLSTEIJN, C. W., VAN IERSEL, A. A., YAP, S. H., NOORDHOEK, J. and BLAAUBOER, B. J., 1994, Interindividual variation in biotransformation and cytotoxicity of bromobenzene as determined in primary hepatocyte cultures derived from monkey and human liver. Human and Experimental Toxicology, 13, 415-421.
32. MILES, J. S., MCLAREN, A. W., FORRESTER, L. M., GLANCEY, M. J., LANG, M. A. and WOLF, C. R., 1990, Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochemical Journal, 267, 365-371.
33. NAMKUNG, M. J., YANG, H. L., HULLA, J. E. and JUCHAU, M. R., 1988, On the substrate specificity of cytochrome P450IIIA1. Molecular Pharmacology, 34, 628-637.
34. NERURKAR, P. V., PARK, S. S., THOMAS, P. E., NIMS, R. W. and LUBET, R. A., 1993, Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B respectively in the rat and mouse. Biochemical Pharmacology, 46, 933-943.
35. O'DONNELL, J. P., KHOSLA, N. B. and DALVIE, D. K., 1998, Metabolism of droloxifene in the CD-1 mouse, Fisher-344 rat and cynomolgus monkey. Xenobiotica, 28, 153-166.
36. OHI, H., TORATANI, S., KOMORI, M., MIURA, T., KITADA, M. and KAMATAKI, T., 1989, Comparative study of cytochrome P-450 in liver microsomes: a form of monkey cytochrome P-450, P-450-MK1, immunochemically cross-reactive with antibodies to rat P450-male. Biochemical Pharmacology, 38, 361-365.
37. OHMORI, S., CHIBA, K., NAKASA, H., HORIE, T. and KITADA, M., 1994, Characterization of monkey cytochrome P450, P450 CMLd, responsible for S-mephenytoin 4′-hydroxylation in hepatic microsomes of cynomolgus monkeys. Archives of Biochemistry and Biophysics, 311, 395-401.
38. OHMORI, S., HORIE, T., GUENGERICH, F. P., KIUCHI, M. and KITADA, M., 1993a, Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys. Archives of Biochemistry and Biophysics, 305, 405-413.
39. OHMORI, S., SAKAMOTO, Y., NAKASA, H. and KITADA, M., 1998, Nucleotide and amino acid sequences of the monkey P450 2B gene subfamily. Research Communications in Molecular Pathology and Pharmacology, 99, 17-22.
40. OHMORI, S., SHIRAKAWA, C., MOTOHASHI, K., YOSHIDA, H., ABE, H., NAKAMURA, T., HORIE, T., KITAGAWA, H., ASAOKA, K., RIKIHISA, T., KANAKUBO, Y. and KITADA, M., 1993b, Purification from liver microsomes from untreated cynomolgus monkeys of cytochrome P450 closely related to human cytochrome P450 2B6. Molecular Pharmacology, 43, 183-190.
41. OHNHAUS, E. E., BRECKENRIDGE, A. M. and PARK, B, K., 1989, Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. European Journal of Clinical Pharmacology, 36, 39-46.
42. OHTA, K., KITADA, M., HASHIZUME, T., KOMORI, M., OHI, H. and KAMATAKI, T., 1989, Purification of cytochrome P-450 from polychlorinated biphenyl-treated crab-eating monkeys: high homology to a form of human cytochrome P450. Biochimica et Biophysica Acta, 996, 142-145.
43. OKAZAKI, O., KURATA, T., HAKUSUI, H. and TACHIZAWA, H., 1992, Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey. Xenobiotica, 22, 439-450.
44. SAKUMA, T., HIEDA, M., IGARASHI, T., OHGIYA, S., NAGATA, R., NEMOTO, N. and KAMATAKI, T., 1998, Molecular cloning and functional analysis of cynomolgus monkey CYP1A2. Biochemical Pharmacology, 56, 131-139.
45. SEDDON, T., LOCKWOOD, G. F. and CHENERY, R. J., 1989, In vitro drug metabolism and pharmacokinetics of diazepam in cynomolgus monkey hepatocytes during culture for six days. Biochemical Pharmacology, 38, 2621-2630.
46. SHARER, J. E., SHIPLEY, L. A., VANDENBRANDEN, M. R., BINKLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231-1241.
47. SHIMADA, T., MIMURA, M., INOUE, K., NAKAMURA, S.-I., ODA, H., OHMORI, S. and YAMAZAKI, H., 1997, Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology, 71, 401-408.
48. SMITH, D. A. and NEALE, M. G., 1983, Metabolism and clearance of proxicromil - studies in rat, hamster, rabbit, dog, squirrel monkey, cynomolgus monkey, baboon and man. European Journal of Drug Metabolism and Pharmacokinetics, 8, 225-232.
49. SOUHAILI-EL AMRI, H., BATT, A. M. and SIEST, G., 1986, Comparison of cytochrome P-450 content and activities in liver microsomes of seven animal species, including man. Xenobiotica 16, 351-358.
50. WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1993, Cytochrome P4502C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in man. Biochemical Pharmacology, 46, 1183-1197.
51. WEAVER, R. J., THOMPSON, S., SMITH, G., DICKINS, M., ELCOMBE, C. R., MAYER, R. T. and BURKE, M. D., 1994, A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochemical Pharmacology, 47, 763-773.
52. WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1995, Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations. Biochemical Pharmacology, 49, 997-1004.
53. WILTSHIRE, H. R., SUTTON, B. M., HEEPS, G., BETTY, A. M., ANGUS, D. W., HARRIS, S. R., WORTH, E. and WELKER, H. A., 1997, Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey an man. Xenobiotica, 27, 557-571.
54. WRIGHTON, S. A. and STEVENS, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.
55. WU, D. F., OTTON, S. V., MORROW, P., INABA, T., KALOW, W. and SELLERS, E. M., 1993, Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. Journal of Pharmacology and Experimental Therapeutics, 266, 715-719.
56. YASUMORI, T., CHEN, I., NAGATA, K., YAMAZOE, Y. and KATO, R., 1993, Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). Journal of Pharmacology and Experimental Therapeutics, 264, 89-94.
57. ZHOU, H. H., ANTHONY, L. B., WOOD, A. J. J. and WILKINSON, G. R., 1990, Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. British Journal of Clinical Pharmacology, 30, 471-475.
58. ZILLY, W., BREIMER, D. D. and RICHTER, E., 1975, Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. European Journal of Clinical Pharmacology, 9, 219-227.